Concepedia

Jean Melville

JM

Statistics

Publications

5

Citations

888

H-Index

5

Active since

1992

Affiliations

Cyclacel Pharmaceuticals (United Kingdom)(Current)

Institut de Chimie des Substances Naturelles

Jean Melville is an author at Cyclacel Pharmaceuticals (United Kingdom) specializing in cell cycle inhibition, medicine, and pharmacology.

Publications per year

1992–2005

5

Publications

5

<i>In vitro</i> and <i>in vivo</i> antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

Steven J. McClue, David Blake, Rosemary G. Clarke et al. · International Journal of Cancer · 2002 · 363 citations · Full text

, , +15

Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1

David E. MacCallum, Jean Melville, Sheelagh Frame et al. · Cancer Research · 2005 · 286 citations · Full text

, , +17

Structure–activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin

Peter M. Fischer, Nikolai Zhelev, S. Wang et al. · Journal of Peptide Research · 2000 · 168 citations

, , +17

The mechanism of action of the tetrapeptide Acetyl‐N‐Ser‐Asp‐Lys‐Pro (AcSDKP) in the control of haematopoietic stem cell proliferation

Sydney K. Robinson, M. Lenfant, Joanna Wdzieczak‐Bakala et al. · Cell Proliferation · 1992 · 45 citations

, , +17

Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.

Anne Rousseau-Plasse, Joanna Wdzieczak‐Bakala, M. Lenfant et al. · PubMed · 1998 · 26 citations

, , +14

1–5 of 5